Disc Medicine, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Disc Medicine, Inc. (IRON) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $73.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-26
- Disc Medicine, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $73.80M, a 72.03% increase from fiscal 2024.
- Disc Medicine, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $42.90M, a 66.93% increase from fiscal 2023.
- Disc Medicine, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $25.70M, a 59.63% increase from fiscal 2022.
- Disc Medicine, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $16.10M, a 22.60% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $73.80M 10-K · filed 2026-02-26 |
| 2024-12-31 | $42.90M 10-K · filed 2026-02-26 |
| 2023-12-31 | $25.70M 10-K · filed 2026-02-26 |
| 2022-12-31 | $16.10M 10-K · filed 2023-03-31 |
| 2021-12-31 | $20.80M 10-K · filed 2022-03-10 |
| 2020-12-31 | $9.90M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |